Division of Pfizer Inc.
Latest From Hospira Inc.
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
- Diagnostic Imaging Equipment & Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Drug Delivery
- Generic Drugs
- Therapeutic Areas
- Hospital Products Division (Abbott)
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
F. Michael Ball, CEO
Thomas E Werner, SVP, Fin. & CFO
Sumant Ramachandra, PhD, SVP, CSO
Marc Yoskowitz, SVP, Strategy & Corp. Dev.
- Contact Info
Phone: (224) 212-2000
275 N. Field Dr.
Lake Forest, IL 60045
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.